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We compared the efficiency of human immunodeficiency virus (HIV-1) vectors that express a marker gene (chloramphenicol
acetyltransferase, CAT) using different promoter elements. In one vector, CAT was expressed under the control of an
internal murine leukemia virus (MuLV) long terminal repeat (LTR). In other vectors, CAT production was regulated by the
HIV-1 LTR; these vectors also contained the HIV-1 tat gene and pol sequences reported to exert cis-acting positive effects
on reverse transcription or gene expression. Vectors employing the Tat-driven HIV-1 LTR exhibited up to 500-fold greater
CAT expression in Jurkat lymphocytes or human peripheral blood mononuclear cells compared with vectors using the
internal MuLV LTR element as a promoter. This difference was not due to improved packaging of the vector RNA into
virions, but to an improved level of gene expression in the target cells. Target cell CAT expression was two- to threefold
higher for the vector containing the pol sequences and was only slightly less than that seen for a trans-complemented env-
deleted provirus. These results indicate that defective HIV-1 vectors with efficiencies of gene transfer and expression
comparable with that of HIV-1 itself are feasible. q 1996 Academic Press, Inc.
INTRODUCTION thermore, given the ability of the wild-type HIV-1 genome
to express multiple gene products via a number of natu-
Retrovirus-mediated gene transfer has provided an ef- rally occurring cis-acting splice control elements, HIV-
ficient means of transferring genes into several cell types 1 vectors should allow the simultaneous expression of
and is the current method of choice for clinical gene several genes of interest. Finally, for the gene therapy of
therapy (Anderson, 1984; Hock and Miller, 1986; Dzierzak HIV-1 infection, HIV-1 vectors can be conveniently made
et al., 1988; Anderson, 1992; van Beusechem et al., 1992; that express products with antiviral activity only upon
Ohashi et al., 1992; Einerhand et al., 1993; Miller et al., infection of the cell by HIV-1. Replication-defective HIV-
1993; Mulligan, 1993; Leiden et al., 1995; Naldini et al., 1 vectors have been previously developed that can be
1996). The primary advantages of retroviral vectors are propagated when essential viral proteins are provided in
the high efficiency of infection, stable proviral integration trans, resulting in a single cycle of replication (Helseth
into the host genome, and high levels of expression in et al., 1990; Page et al., 1990; Poznansky et al., 1991;
a wide range of cell types (Varmus, 1988). Most currently Buchschacher and Panganiban, 1992; Parolin et al., 1994;
used retroviral vectors are based on amphotropic murine He and Landau, 1995). The generation of replication-
leukemia viruses (MuLV-A). competent viruses can be minimized by providing the
It may be possible to take advantage of the unique trans-acting viral functions on two separate expression
properties of human immunodeficiency virus (HIV-1) to plasmids (Poznansky et al., 1991). Currently, the effi-
augment the utility of retroviral vectors. HIV-1 vectors ciency of gene transfer that has been obtained with HIV-
have been shown to be able to infect growth-arrested based vectors is significantly lower than that achieved
cells refractory to MuLV-A vectors (Lewis et al., 1992), a by the existing MuLV-A-based systems. To overcome this
property that may be useful for delivering genes to resting problem, HIV-1 vectors must be modified to attain a high
target cells. HIV-1 can be efficiently pseudotyped by efficiency of both transduction and gene expression. Effi-
MuLV-A envelope glycoproteins (Chesebro et al., 1990; cient transduction requires the optimal positioning of vi-
Landau et al., 1991), allowing an expansion of the host ral cis-acting sequences within the vector and the avail-
range of HIV-1 vectors beyond CD4-positive cells. Fur- ability of packaging cell lines capable of producing high
titers of replication-defective recombinant viruses. Sus-
tained expression of exogenous genes in target cells
1 Present address: Istituto Superiore di Sanita´, Rome, Italy. depends upon the choice of promoters and the location2 To whom correspondence and reprint requests should be ad-
of the transcriptional units within the vector framework.dressed at Division of Human Retrovirology, Dana-Farber Cancer Insti-
Accordingly, the expression of a gene of interest can betute, 44 Binney St., Boston, MA 02115. E-mail: Joseph_Sodroski
@DFCI.Harvard.edu. driven by a heterologous promoter at an internal site
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within the vector or by the retroviral promoter present in plasmids contain the complete 5* LTR, flanking leader
sequences, gag sequences up to the SphI site (nucleo-the 5* LTR. The latter strategy can take advantage of
alternative splicing mechanisms that complex retrovi- tide 989), and an env fragment from Bgl II (nucleotide
7199) to BamHI (nucleotide 8053), inclusive of the Rev-ruses such as HIV-1 adopt to express high levels of
regulatory proteins (Haseltine, 1988). One of these pro- responsive element (RRE). The v653 RSC vector is a de-
rivative of the v653 RSN vector previously described (Pa-teins, Tat, is essential for HIV-1 replication (Dayton et al.,
1986; Fisher et al., 1986). Tat has been shown to activate rolin et al., 1994), with the CAT gene located 3* to the
SL3-3 U3 LTR sequences, in place of the neo gene. Totranscription in trans from the HIV-1 LTR, increasing the
steady-state levels of all HIV-1 mRNAs up to 1000-fold make the v653 RtatpC vector, an MscI–BamHI fragment
(nucleotides 4132 to 8053), containing an env deletion(Sodroski et al., 1984, 1985; Arya et al., 1985). Here we
report the design of new HIV-1 vectors in which the ex- between the Bgl II sites (at nucleotides 6619 and 7199),
was used to replace the SphI–BamHI fragment (nucleo-pression of a heterologous gene is controlled by the Tat-
driven HIV-1 LTR. The ability of these HIV-1 vectors to tide 989 to 8053) of the HXBc2 provirus. The inserted
fragment, which contains sequences from pol, tat, andbe packaged into virions and to mediate stable gene
transfer into human T-lymphocyte cell lines and human the 5* end of env, was introduced by joining Bcl I linkers
at the MscI site (nucleotide 4132) of the provirus. Theperipheral blood mononuclear cells (PBMCs) was com-
pared with that of a previously reported HIV-1 vector, v653 RtatC vector was constructed similarly, except that
a PflM I–BamHI fragment (nucleotides 4878 to 8053),which utilizes a heterologous internal promoter.
containing an env deletion between the Bgl II sites (at
nucleotides 6619 and 7199) and blunted at the 5* end,MATERIALS AND METHODS
was used to replace the SphI–BamHI segment (nucleo-
Construction of the packaging system and vectors
tides 989 to 8053) of the HXBc2 provirus. In the v653
RtatpC and v653 RtatC vectors the CAT gene has beenThe main features of the packaging system and vec-
tors are illustrated in Figs. 1A and 1B. HIV-1 related se- cloned at the BamHI site (nucleotide 8053). In all vectors
the sequences 3* to the CAT gene include HXBc2 se-quences were derived from the HXBc2 provirus (Ratner
et al., 1985) with the exception of the vpu and vpr se- quences from the BamHI site (nucleotide 8053) to the 3*
boundary of the LTR.quences, which were derived from the pNL4-3 molecular
clone (Adachi et al., 1986). The nucleotide sequences
Cell culture and transfectionin the packaging and vector constructs are numbered
according to Ratner et al. (1985). The packaging system
Jurkat cells were grown in RPMI 1640 supplemented
(Fig. 1A) includes the CMVDP1DenvpAvpu/vpr and the
with 10% fetal calf serum. To assess promoter function,
CMVenvDXho plasmids. The CMVDP1DenvpAvpu/vpr
Jurkat cells (7–10 1 106) were transfected by the DEAE-
plasmid is a derivative of the CMVDP1DenvpA construct
dextran procedure (Queen and Baltimore, 1983) with 10
previously described (Parolin et al., 1994). To generate
mg of the v653 RtatpC vector or equivalent molar amounts
the CMVDP1DenvpAvpu/vpr plasmid, an NdeI–NdeI
of the other constructs examined and harvested 3 days
fragment (nucleotide 4703 to 5981) of the CMVDP1D-
later. Equivalent amounts of cell protein extracts were
envpA plasmid was replaced by the corresponding se-
used to measure the level of CAT activity, as previously
quence from the pNL4-3 molecular clone (Adachi et al.,
described (Sodroski et al., 1984).
1986), introducing functional vpu and vpr genes. The
CMVenvDXho plasmid expresses the HIV-1 rev and env Generation of recombinant virus and transduction
genes under the control of the cytomegalovirus immedi-
ate early promoter. The CMVenvDXho construct was de- Recombinant viruses were generated by cotransfec-
tion of COS-1 cells with the packaging system plasmidsrived from the CMVenv plasmid. The latter plasmid con-
tains the Sal I– XbaI fragment (nucleotide 5496-3* flanking along with the vector, as described previously (Parolin
et al., 1994), except for the following modifications: (i) 10sequences) of the HXBc2 provirus cloned into the XhoI
and XbaI sites of the pcDNAI/Amp plasmid (Invitrogen). mg of the CMVDP1DenvpAvpu/vpr plasmid, 5 mg of the
CMVenvDXho plasmid, and 7 mg of the vector were usedThe CMVenvDXho construct was derived by digesting
CMVenv with XhoI and XbaI, blunting the ends with the for transfection experiments; (ii) the recombinant virus
was harvested 65 hr following transfection without filtra-Klenow fragment of DNA polymerase I and ligation. This
procedure removes the 3* LTR and flanking sequences. tion. PBMCs were obtained from healthy donors by Ficoll-
Hypaque density gradient separation and grown for 48–Both the CMVDP1DenvpAvpu/vpr and CMVenvDXho
plasmids contain polyadenylation signals derived from 72 hr with phytohemagglutinin (PHA) (1 mg/ml) (Murex
Diagnostics) in RPMI medium supplemented with 10%SV40.
The marker gene in all the HIV-1 vectors used herein fetal calf serum. Eighteen hours before the infection, hu-
man interleukin 2 (Collaborative Research) was added(Fig. 1B) encodes chloramphenicol acetyltransferase
(CAT) and was contained on a 0.78-kb BamHI fragment to the culture (5%). Cell density was maintained at a
constant level (0.5–1.0 1 106 cell/ml) during all proce-derived from the pCM4 plasmid (Pharmacia). All vector
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dures. Equivalent reverse transcriptase (RT) units (from early promoter in the env expressor plasmid, to eliminate
the possibility of LTR-mediated homologous recombina-27,500 to 93,500 cpm in different experiments) of COS-1
supernatants were used to infect 1.5–2.0 1 105 Jurkat tion between the HIV-1 vector and the packaging compo-
nents, and (ii) inclusion of the vpu and vpr genes in thecells, in a total volume of 5 ml. Approximately 1 1 107
PBMCs were infected with recombinant virus equivalent gag-pol-expressing plasmid.
Previous studies have identified the sequences thatto 1 1 105 cpm of RT activity. To assess the transduction
ability of the vectors, the cells were collected on different are necessary and sufficient for HIV-1-mediated gene
transfer into human lymphocytes (Lever et al., 1989; Al-days and lysed. Protein concentrations in the lysates
were determined with the Pierce protein determination dovini and Young, 1990; Clavel and Orenstein, 1990; Poz-
nansky et al., 1991; Hayashi et al., 1992). These encom-kit using BSA as a standard. Equivalent amounts of pro-
tein were used for determination of CAT activity, as pre- pass the HIV-1 LTRs and immediate flanking sequences,
including the regions implicated in viral RNA packagingviously described (Sodroski et al., 1984). Only values in
the linear range of CAT activity were used to calculate located between the 5* LTR and the gag gene initiation
codon. At the 3* end of the genome, a polypurine tract isthe relative CAT activities shown in Fig. 2.
important for plus-strand DNA synthesis during reverse
transcription. Recently, we have observed that inclusionDetermination of vector RNA in virions and in
packaging cell lines of 653 nucleotides of gag sequences along with the Rev-
responsive element (RRE) in the HIV-1 vector improved
Cytoplasmic RNA was harvested from COS-1 cells gene transfer efficiency into human lymphocytes (Parolin
transfected with the packaging system and with different et al., 1994). All of the vectors tested herein contain these
vectors as reported elsewhere (Parolin et al., 1994). Vi- sequences.
rion RNA was purified from particles released into the This study was designed to determine whether addi-
supernatant of the transfected cultures after pelletting tional cis- or trans-acting HIV-1 sequences would in-
through 20% sucrose. RNA samples were adjusted for crease the efficiency of HIV-1 vectors. For comparison
the amount of p24gag in the virion pellets as described with previously characterized HIV-1 vectors, the v653
previously (Dorfman et al., 1993). Levels of vector RNA RSC vector was constructed and included in this study.
in the samples were quantified by RNase protection anal- The v653 RSC vector is identical to the previously de-
ysis using a uniformly labeled RNA probe synthesized signed v653 RSN vector (Parolin et al., 1994), except that
from the MroI-linearized pTZ18U/MX plasmid as de- the neo gene in the latter construct has been replaced
scribed previously (Parolin et al., 1994). This plasmid con- by the chloramphenicol acetyltransferase (CAT) gene.
tains 5* long terminal repeat (LTR) and untranslated se- The CAT gene was used to investigate promoter strength
quences (HXBc2 nucleotides 308 to 815), covering the and transcriptional activity in the target cells. In the v653
major splice donor site upstream of the gag gene, in an RSC vector, the expression of the CAT gene is regulated
antisense orientation to a T7 RNA polymerase promoter by an internal promoter, the U3 sequences derived from
(Dorfman et al., 1993, 1994). All experiments were carried the SL3-3 ecotropic murine leukemia virus (Celander and
out under conditions in which excess probe was present. Haseltine, 1984; Losardo et al., 1990). Compared with
RNase-resistant fragments were separated on a 4.5% the v653 RSC vector, the v653 RtatC and v653 RtatpC
polyacrylamide–8.3 M urea gel, dried, and subjected to vectors contain, in addition, the tat coding sequence and
autoradiography. The relative intensity of bands on the the 5* end of the env gene (nucleotides 4878 to 6619).
gel was quantitated by densitometric analysis. The v653 RtatC and v653 RtatpC vectors express the CAT
gene under the transcriptional control of the HIV-1 LTR.
RESULTS In these constructs, the CAT gene can be expressed
from a subgenomic mRNA generated by the same splic-Production and testing of vectors
ing events used for the natural HIV-1 nef message.
In addition to the polypurine tract (PPT) located at theTo minimize the generation of replication-competent
virus, the packaging component was produced by two border of the 3* LTR, HIV-1 and other lentiviruses contain
another PPT copy, located within the pol coding regiondifferent plasmids (Fig. 1), as previously described (Pa-
rolin et al., 1994). One plasmid expresses the gag, pol, (Charneau and Clavel, 1991; Charneau et al., 1992). This
central PPT is likely to be used as a second origin fortat, vif, vpu, and vpr genes and the other expresses the
env and rev genes. Both plasmids contain the cytomega- plus-strand viral DNA synthesis (Charneau and Clavel,
1991; Charneau et al., 1992). Furthermore, functional en-lovirus immediate early promoter and SV40 polyadenyla-
tion signals and lack sequences shown to be important hancer sequences within the pol gene have been identi-
fied (Verdin et al., 1990; Van Lint et al., 1994). To deter-for efficient HIV-1 packaging (Lever et al., 1989; Aldovini
and Young, 1990). Compared to the packaging compo- mine whether the presence of these PPT and enhancer
sequences in the vector influences the efficiency of genenent previously utilized in our laboratory (Parolin et al.,
1994), two principal modifications were made: (i) replace- transfer, a 746-bp sequence (nucleotides 4132 to 4878),
encompassing the PPT sequence as well as part of thement of the 5* LTR by the cytomegalovirus immediate
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FIG. 1. Structure of the packaging system and vector plasmids. (A) Packaging system. The CMVDP1DenvpAvpu/vpr and CMVenvDXho plasmids
are shown. HIV-1 genes that are functionally active are indicated. (B) HIV-1 vectors. The expression of the marker gene (CAT) is regulated by the
SL3-3 U3 LTR sequences (SL3) in the v653 RSC vector and by the HIV-1 LTR in the v653 RtatpC and v653 RtatC vectors. Positions of some restriction
endonuclease sites in the parental provirus are also indicated. SD, splice donor; SA, splice acceptor; RRE, Rev-responsive element; SV40 poly(A),
polyadenylation signal from SV40; D19bp, deletion of sequences important for HIV-1 RNA packaging.
enhancer region, was deleted from the v653 RtatpC vec- inserted CAT gene, aliquots of transduced cells were
collected on different days following infection. Resultstor, generating the v653 RtatC vector. In all vectors the
of CAT assays carried out on these samples are sum-polyadenylation signal for the CAT gene transcript was
marized in Fig. 2. Comparable CAT activity was ob-provided by the 3* LTR sequences.
served in Jurkat cells transduced with either the v653
RtatpC vector or the HXBDenvCAT construct (Fig. 2A).Effect of inclusion of tat/pol sequences on vector-
CAT activity in Jurkat cells transduced with the v653mediated gene transfer
RtatC vector was lower than that observed in cells
The ability of the newly designed HIV-1 vectors to transduced with the v653 RtatpC vector, suggesting
mediate gene transfer was analyzed by transduction that the presence of pol sequences in the vector influ-
experiments using Jurkat T lymphocytes and PHA-stim- enced either CAT gene transfer or expression. CAT
ulated PBMCs as target cells. COS-1 cells were activity in Jurkat cells transduced with the v653 RSC
transfected with each HIV-1 vector along with the two- vector was approximately 500-fold lower than that ob-
component packaging system described above. In par- served for the v653 RtatpC vector. In all experiments,
allel, COS-1 cells were also transfected with the CAT activity in the Jurkat cells peaked between 10 and
HXBDenvCAT construct together with the env ex- 25 days of infection. The CAT activity declined thereaf-
pressor plasmid. The pHXBDenvCAT construct con- ter but was still readily detectable at 75 days following
tains an HIV-1 provirus with an env deletion and carries infection.
the CAT gene in place of the nef gene (Helseth et Similar experiments were carried out using PHA-stim-
al., 1990). Reverse transcriptase activity in the culture ulated PBMCs as target cells. As shown in Fig. 2B and
supernatants was determined 65 hr following transfec- Table 1, CAT activity was detected in the target PBMCs
tion, and equivalent reverse transcriptase units were transduced with the v653 RtatpC and v653 RtatC vectors,
as well as with the pHXBDenvCAT virus. The relativeadded to the target cells. To test for expression of the
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FIG. 2. Transduction efficiency of HIV-1 vectors in Jurkat lymphocytes and peripheral blood mononuclear cells (PBMCs). Supernatants from COS-
1 cells, cotransfected with the packaging component along with each of the vectors, were incubated with Jurkat lymphocytes (A) and PBMCs (B)
and CAT activity was measured on different days. The percentage conversion of chloramphenicol to its acetylated forms is shown. (A) The mean
CAT activity derived from three experiments is presented. (B) An autoradiograph of a representative CAT assay is shown.
efficiencies of the different HIV-1 vectors in PBMC target site, was used to distinguish between spliced and un-
spliced vector RNA (Fig. 3). Protected fragments of thecells were comparable to those observed in Jurkat lym-
phocytes. Experiments in which equivalent amounts of expected size for unspliced (355 nucleotides) and spliced
(287 nucleotides) were detected in the cytoplasmic RNA.the vector and target cell preparations were used indi-
cated that the HIV-1 vectors can transduce human Unspliced RNA predominated in virion RNA preparations.
Only minor differences in the intensity of the specificallyPBMCs with an efficiency that is at least as high as that
seen for Jurkat T cell lines (data not shown). protected fragments were observed among the different
vectors. These results demonstrate that the packaging
Effect of vector design on RNA packaging efficiencies of the v653 RtatpC, v653 RtatC, and v653
RSC vectors are similar and comparable with that of theThe varying levels of CAT activity associated with the
previously described v653 RSN vector (Parolin et al.,HIV-1 vectors could be due to differences in gene transfer
1994). Thus, differences in packaging efficiency are notefficiency or in the efficiency of gene expression in the
likely to account for the observed differences in targettarget cells, or both. To determine whether differences
cell CAT activity among the various vectors examined.in the efficiency of packaging the vector RNA into virions
were responsible for the observed differences in vector-
Effect of vector design on gene expression in themediated gene transfer, the steady-state levels of vector
target cellsRNA in virions and in the cytoplasm of the transfected
COS-1 cells were measured by an RNase protection
To evaluate whether the vector design influenced theassay. A probe (probe MX) complementary to the viral
efficiency of CAT gene expression in the target cells,long terminal repeats and untranslated leader se-
Jurkat lymphocytes were directly transfected with vectorquences, encompassing the HIV-1 major splice donor
DNA. Three days following transfection, cells were lysed
and similar amounts of cell protein extracts were used
TABLE 1 to measure the level of CAT activity. The results of two
representative experiments are reported in Fig. 4. LowCAT Activity in Human PBMC Target Cellsa
CAT activity was obtained with the v653 RSC vector. The
Day following transduction CAT activities associated with transfection of the v653
RtatpC and v653 RtatC vectors were approximately 500-
HIV-1 Vector 3 8
fold higher than that of the v653 RSC vector. Since the
CAT activities observed for the v653 RtatpC and v653v653 RSC 0.20 { 0.13 0.25 { 0.07
v653 RtatC 9.0 { 2.8 28.1 { 8.7 RtatC vectors were comparable, the presence of the pol
v653 RtatpC 26.4 { 2.2 68.5 { 9.2 sequences had little effect on the expression efficiency
HXBDenvCAT 29.7 { 7.9 66.3 { 22.6 of the vectors. Compared with cells transfected with the
v653 RtatpC plasmid, Jurkat cells transfected with thea The percentage conversion of chloramphenicol to its acetylated
pHXBDenvCAT construct exhibited two- to threefold lessforms is shown. The means and standard deviations are derived from
two separate experiments. CAT activity.
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FIG. 3. RNase protection analysis of cytoplasmic and virion RNA. (A) The expected annealing of the MX probe with both vector DNA and RNA
is shown. The MX probe is complementary to 355 and 244 nucleotide fragments of unspliced vector RNA derived from the 5* and 3* ends, respectively.
Annealing of the MX probe with spliced vector RNA is expected to yield a 287-nucleotide fragment from the 5* end and a 244-nucleotide fragment
from the 3* end. (B) RNase protection analysis of cytoplasmic RNA derived from the packaging cells or of viral RNA. The RNA samples were derived
from COS-1 cells transiently transfected with plasmids expressing the packaging system alone (lane 1) or with the packaging system plus v653
RSC (lane 2), v653 RtatpC (lane 3), v653 RtatC (lane 4) or v653 RSN (lane 5).
DISCUSSION the placement of the CAT gene. The latter feature allows
CAT to be expressed from multiply spliced messenger
In this study, HIV-1 vectors using the Tat-regulated RNAs that are particularly abundant in cells, like the tar-
viral LTR to express a heterologous CAT gene were com- get cells, that lack expression of the HIV-1 Rev protein.
pared with those using a heterologous internal promoter For similar reasons, Tat expression in the target cells
derived from the SL3-3 murine leukemia virus LTR U3 should also be favored.
region. The latter element has been shown to exhibit Inclusion of pol sequences, which contain the second
substantial promoter activity in human and murine B and polypurine tract (PPT) and part of the enhancer region,
T lymphocytes (Celander and Haseltine, 1984; Losardo in the vector resulted in a two- to threefold increase in
et al., 1990). Although the strength of the SL3-3 LTR pro- gene transfer efficiency. Direct transfection experiments
moter is decreased by placement in an internal position indicated that only a small part of this increase appeared
within HIV-1 vectors (data not shown), the activity is suffi- to result from a greater efficiency of vector gene expres-
cient to allow selection of cells transduced with HIV-1 sion in the target cells. However, it remains a formal
vectors expressing neomycin phosphotransferase (Pa- possibility that the enhancer sequences identified in this
rolin et al., 1994). Compared with this prototypic HIV-1 pol segment exhibit greater activity in the context of the
vector, HIV-1 vectors using the Tat-regulated LTR exhib- integrated vector sequences than in the context of tran-
ited up to 500-fold greater CAT expression in Jurkat lym- siently transfected plasmid DNA. The presence of the
phocytes or human PBMCs. The majority of this improved second PPT in these pol sequences, which has been
CAT expression can be explained by the increased effi- reported to act as an additional site for initiation of HIV-
ciency with which the Tat-regulated vectors express CAT 1 plus-strand synthesis (Charneau et al., 1992), probably
in the target cells. The likely explanations for the effi- also contributes to the observed positive effect on gene
ciency of CAT expression in these vectors are the transfer.
The expression of the CAT gene by the HIV-1 vectorsstrength of the Tat-driven HIV-1 LTR as a promoter and
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The efficiency of gene transfer and expression ob-
served for the v653 RtatpC vector approaches that of
the nearly full-length env-deleted HIV-1 provirus con-
tained in the HXBDenvCAT construct. Assuming that
the transduction of HXBDenvCAT sequences is as effi-
cient as that of a complete HIV-1 genome, this result
suggests that defective HIV-1 vectors could potentially
achieve titers and efficiencies approaching those of
HIV-1 itself. The optimization of vector components re-
ported herein should help to achieve that end. The opti-
mization of stable packaging systems will be ad-
dressed in future studies.
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